Investors Hangout: DEA Witness Denial Sparks Outcry Among Advocates

Published on October 7, 2024 in Investors Hangout by Owen Jenkins.

The Drug Enforcement Administration (DEA) has caused quite a stir by denying testimony from important witnesses just before scheduled hearings on the potential classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). This decision has led to significant backlash from advocates, most notably the Students for Sensible Drug Policy (SSDP), who claim the DEA is stifling essential scientific discussions.

Read more in Investors Hangout here.